Patient groups’ perceptions of drugmakers with large U.S. footprints have shifted in the past year as the businesses have contended with political pressures, PatientView said.
The findings come from PatientView’s annual survey of more than 2,000 patient groups worldwide. The research company found that patient groups “markedly shifted their perceptions of the corporate reputation of many individual pharma companies.” Such big year-on-year shifts are rare, PatientView said, and the feedback suggests “radical changes in market circumstances are largely responsible for the divergence.”
Volatility in the ranking of drugmakers’ reputations centered on businesses with large U.S. footprints. Changes were “driven primarily
Our editorial team includes several staff writers, each contributing their specialized knowledge to enhance the depth and breadth of our event and story coverage.